Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One this days it will go above $0.20 if you keep predicting it. LOL
Merck CEO is on CNBC right now talking about the good possibility of having therapeutics in capsule form soon. No additional details. Hmmmm....
I rarely post here. Please look back at my posts to you and respond with anything that was argumentative etc.
I don't believe you will find one thing.
Your very defensive????
I never complained or said I don't want to hear others who do their own due diligence.
Just having a back and forth conversation but you seem to get very defensive. Why???
I think you may have some good input for this board but you get frustrated if someone has questions or contradicts what you say. Just relax and let's have a productive discussion.
There hasn't been a form 4 backing that up. There also has not been that type of volume to back that up.
Either we are all missing something or someone is either lying or there is a misunderstanding somewhere.
I hope it's true that he has been buying shares but we have no indication of that recently.
See below from the 10-15-2020 10-K
Name and Address of Beneficial Owner
Amount and Nature of Beneficial Ownership Percentage of Class
Christopher Bunka; Kelowna BC Canada 14,308,148(1) 15.89%
Nicholas Baxter; Aberdeenshire, UK* 480,000(2) 0.53%
John Docherty; Toronto, Ontario 2,872,250(3) 3.19%
Ted McKechnie; Toronto, Ontario* 545,738(4) 0.61%
Allan Spissinger; Langley, BC* 769,166(5) 0.85%
Brian Quigley; Richmond, VA* 100,000(6) 0.11%
Directors and Executive Officers as a Group (6 persons) 19,075,302 21.18%
If Chris purchased more shares in the last 2 weeks, we should already know about it, no?
Key words:
In addition, this patent includes important method of treatment claims for a broad range of disease conditions including use of:
I believe this is the beginning of Lexaria rolling out positive releases to get the share price up to eliminate or lower the RS ratio leading up to the up-list.
RecoveryRx Patient Success
Published on October 20, 2020
Keith Nalepka
Keith Nalepka
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
6 articles
Following
RecoveryRx is a clinically proven, drug-free medical device indicated for postoperative pain relief. The case studies below suggest that RecoveryRx is valuable in the perioperative environment as well, leading to lower pain scores, less medication usage and increased functionality. RecoveryRx has the abilty to help 1000s of patients who share a similar diagnosis as the ones below - with the help of a great sales team, we are seeing an immediate impact in doctors offices.
Patient 1: 61 years old
Diagnosis: Spinal stenosis/SI joint pain. Patient is currently in PT for this issue and will see the PA/Neurosurgeon shortly, after over a month of PT.
Intervention: Prior to RecoveryRx use, the patient experienced pain while getting out of bed, inhibiting their ability to move. A RecoveryRx device was applied to the patient's area of pain. As of this summary, the patient had the unit on their area of pain for 3 weeks. They are wearing it in the bath/shower and do not take it off unless the tape (used to adhere the device to the body) is wearing off, at which fresh tape immediately re-applied.
Observations: The patient noted a significant reduction in pain after 2 days of wearing the device. Further, the patient noted that pain no longer inhibited their ability to move, i.e. get out of bed.
Patient 2: 53 years old
Diagnosis: Previous FX (fracture) and dislocation; Lateral epicondylitis, 2 previous fractures with avulsion, osteo formations (bone spurs) and multiple dislocations.
Intervention: This patient is very active and does not want to quit working out or quit playing hockey. They have had injections in the elbow to help with this pain in an attempt to avoid surgery, but with little to no success. The RecoveryRx device was applied to the area of pain, concurrently with the scheduled injection.
Observations: The patient is now doing very well and has reported significantly less pain. They are doing very well and playing hockey again as well as working out on a daily basis, indicating that RecoveryRx was able to restore functionality.
BOOM!!!!!!
We have ignition!!!
Get ready for lift off!!!!!!
Let's get out of the trips for ever and hit over a 100,000,000 volume today!
BUILDING AN EMPIRE!!!!!!!
BUILDING AN EMPIRE!!!!!
Click for latest tweet!!!
The video is from February 2019?
I call it a "nice buying opportunity"
I picked up another 20,000 shares at 0.185
Doing my part, who's next?
The interview was dated June 2019. Not an update..
One of Cannadips claims to fame is they contain no nicotine.
Not sure Altria is a good match for that.
If there is an announcement to be made, it will be released after the close today or before the open tomorrow, This is due to the Holiday in Canada today.
Easy 1 mil volume
I believe the statement below is the key. I believe Altria made a business decision that further investment for exclusivity was not the direction they needed to go in. I believe they will utilize the technology. This may very well be a win win for Lexaria. Looking forward to cheap shares tomorrow morning!!!
"Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results."
You seem to be the only one who posts on the LXX board?
Hoping for a dip on Monday. Ready to load up!!!!!
We wouldn't be very good investors if we're counting on this one deal to make or break the company.
There's way more potential here than this one deal.
We don't even know if the Altria deal is a total failure yet. I think we are not done with Altria yet!!
Bunka is not stupid. There's way more to this plan/story than we know....
I predict the the closing price today is $0.24.
Good news will be released Monday after the close or Tuesday before the open.
Agreed if bad news it will be released after the close today.
I believe it will be very good news and will be released Monday or Tuesday.
Time will tell ...
If news is released tomorrow, it will be bad. Good news will be saved for early next week...
Not a great presentation this time and he sounded depressed?
Can't help but think this is going to mean something for next week????
Lexaria 8-K
ActiPatch Facebook post this week
Why OEM? Retailers on a national level reset the store planograms once a year. In the pain category that happens in the fall annually. Retailers first question is always, "what are you going to spend to get this to sell?" If we were to launch the brand nationally, it would take on the order of a $3-5 million advertising campaign. The OEM strategy allows us to work with partners who have an existing retail presence. The ones we are in talks with have 25k plus retailer store distribution. For us to do that ourselves, it would take 5-7 years to get into that many stores. Retailers also would charge us 3-5 in just placement/slotting fees in addition to the marketing money. The OEM model allows us to fast forward that process, maintain 60% plus margins and have the marketing cost handled by the partner.
Secondly, if you place a brand without recognition/advertising into a large retailer it will fail. Just being on the shelf in a big box store means nothing. Third, is as basic as logistics. Retailers require a large infrastructure to deliver product, this is better done with a partner who has this in place. The partners we are finalizing things with will give rapid exposure to 25k plus retail outlets. ActiPatch needs consumer education to maximize sales. Partners have the cash to make this happen. In summation, the margins are better with OEM, volume is also higher. It drives brand exposure and customer awareness. I understand things never happen quick enough. If you don't build things correctly in retail, no matter how good the product is, you are destined to fail. We are planning a win and we have made tremendous strides in discussions with great partners.
All material news will be issued via a press release when appropriate.
KELOWNA, BC - TheNewswire - June 4, 2020 - Christopher Bunka, Chief Executive Officer and director of Lexaria Bioscience Corp. (the " Company "), (CNSX:LXX.CN) of 100 - 740 McCurdy Road, Kelowna, BC V1X 2P7, announces his intention to file an early warning report (the " EWR ") in accordance with National Instrument 62-104 - Take-Over Bids and Issuer Bids (" NI 62-104 ") and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (" NI 62-103 ") as promulgated by the Canadian Securities Administrators.
Mr. Bunka intends to file an EWR to report the acquisitions of common shares of the Company (the " Shares ") or securities exercisable to purchase Shares, that occurred over a period of five years pursuant to: (i) open market acquisitions on the OTCQX (LXRP) or the CSE (LXX); (ii) the occurrence of a stock split by the Company; (iii) option issuances and/or exercises (iv) warrant issuances and/or exercises; and (v) private placement transactions, the most current of which is described below (the " Current Transaction ").
In connection with the Current Transaction, Mr. Bunka acquired 200,000 units comprised of 200,000 Shares and 200,000 share purchase warrants pursuant to a private placement financing of an aggregate 8,866,211 Units for aggregate gross proceeds of US$2,039,228, which the Company conducted on May 6 and May 11, 2020. Mr. Bunka paid a price of US$0.23 (CDN$0.32) per unit for an aggregate purchase price of US$46,000 (CDN$64,000).
Following the Current Transaction, Mr. Bunka, directly and indirectly through his holding company, holds an aggregate of 13,408,148 Shares on a non-diluted basis representing 15% of the Company's issued share capital or 14,308,148 Shares on a partially diluted basis representing 15.8% of the Company's diluted share capital. Each Share entitles the holder thereof to one vote at any meeting of shareholders.
Mr. Bunka acquired the additional Shares and warrants for investment purposes only. Mr. Bunka holds his securities in the Company primarily for investment purposes but may, when allowed pursuant to US and Canadian securities laws, and pursuant to favourable market conditions, increase or decrease his respective beneficial ownership and control or direction over the Shares through market transactions, related financial instruments, private agreements, incentive awards, exercise of convertible securities or otherwise.
This news release is issued pursuant to NI 62-103 in connection with the filing of the EWR. To obtain a copy of the EWR filed by Chris Bunka, refer to the Company's SEDAR profile at http://www.sedar.com or request a copy from Lexaria Bioscience Corp. 100 - 740 McCurdy Road, Kelowna, BC V1X 2P7
Copyright (c) 2020 TheNewswire - All rights reserved.
© 2020 Canjex Publishing Ltd. All rights reserved.